⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Buckeye Partners Announces Donald R. Sinclair as Chairman
globenewswire.com
WES
DUK
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
DYN
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
globenewswire.com
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
globenewswire.com
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com
DYN
Form 8-K
sec.gov
DYN